InflammX Therapeutics Enters Option Agreement with Bausch + Lomb
InflammX Therapeutics, Inc. has announced an option agreement with Bausch + Lomb, granting the latter the right to acquire the company. This collaboration signals a potential advancement in the development and delivery of innovative treatments for retinal diseases.
Focus on Retinal Disease Therapeutics
InflammX Therapeutics’ pipeline features an orally dosed therapeutic candidate designed to address intermediate age-related macular degeneration (iAMD) and diabetic retinal eye disease. These conditions affect millions worldwide, and InflammX is focused on filling the significant unmet needs in these areas.
Terms of the Agreement
Under the terms of the agreement:
• Exclusive Option: Bausch + Lomb has secured the exclusive right to acquire InflammX Therapeutics.
• Milestone-Driven Period: The option is tied to the achievement of specified development milestones during the agreed-upon option period.
• Timeline: The agreement was finalized in December 2024.
No financial terms of the deal have been disclosed.
Insights from Key Leaders
Yehia Hashad, Chief Medical Officer and Executive Vice President of Research & Development at Bausch + Lomb, expressed optimism about the collaboration:
“We see tremendous potential in combining our resources and expertise with InflammX’s innovative approach to retinal disease treatment.”
Brian Levy, CEO of InflammX Therapeutics, emphasized the strategic benefits of the agreement:
“Partnering with Bausch + Lomb offers a unique opportunity to accelerate the development of our pipeline and bring our therapies to patients worldwide. We share a common vision of improving outcomes for individuals affected by retinal disease, such as iAMD, which represents a majority of patients diagnosed with AMD, and for which there is no currently approved treatment.”
Looking Ahead
This agreement paves the way for potential advancements in the treatment of iAMD and diabetic retinal diseases. If the collaboration leads to the successful development of InflammX’s pipeline, it could mark a significant step forward in addressing the needs of patients with retinal diseases globally.
Reference:
